Institute Of Cancer Research, United Kingdom

This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …

This early-phase trial tests two experimental drugs, defactinib and VS-6766, together in people with advanced solid tumors that have stopped responding to standard treatments. The study includes patients with certain lung, ovarian, endometrial, and pancreatic cancers. The main go…

This early-stage trial tests whether adding tepotinib to the immunotherapy pembrolizumab (Keytruda) can help treat advanced non-small cell lung cancer (NSCLC) that doesn't respond to immunotherapy alone. The study includes about 19 adults with NSCLC, some with a specific MET gene…

This study looks at men with advanced prostate cancer that no longer responds to hormone therapy. Researchers check if certain inherited gene changes make the cancer more sensitive to the chemotherapy drug carboplatin. About 305 men will first have genetic testing, and those with…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapy can lower the chance of breast cancer returning in postmenopausal women with a high-risk type. About 123 participants will receive either hormone therapy alone or with abemaciclib for up to 2…

This study looks at whether yearly PSA tests can find prostate cancer early in men who have inherited certain gene mutations (BRCA1, BRCA2, or mismatch repair genes) that raise their risk. About 3,500 men aged 40-69, both with and without these mutations, will be screened and com…

This study looks at blood samples from 25 cancer patients receiving radiation therapy. Researchers want to find specific genes that show how each person's body responds to radiation. The goal is to better understand individual reactions and possibly personalize radiation treatmen…

This study aims to find genetic changes that increase the risk of prostate cancer, especially in younger men or those with a family history. Over 23,000 men with prostate cancer are participating, providing blood or tissue samples for genetic analysis. The goal is to better under…

This study looks at whether a simple genetic test can identify men who are more likely to have prostate cancer, so screening can be focused on them. About 300 Caucasian men aged 55 to 69 will provide a DNA sample and, if their genetic risk score is high, they will be offered a pr…